Atherosclerosis
Volume 213, Issue 1 , Pages 77-84 , November 2010

Role of transglutaminases in cuff-induced atherosclerotic lesion formation in femoral arteries of ApoE3 Leiden mice

  • Hanke L. Matlung

      Affiliations

    • Department of Biomedical Engineering and Physics, Academic Medical Center, PO Box 22700, 1100 DE Amsterdam, The Netherlands
    • ,
  • Ed VanBavel

      Affiliations

    • Department of Biomedical Engineering and Physics, Academic Medical Center, PO Box 22700, 1100 DE Amsterdam, The Netherlands
    • ,
  • Jeroen van den Akker

      Affiliations

    • Department of Biomedical Engineering and Physics, Academic Medical Center, PO Box 22700, 1100 DE Amsterdam, The Netherlands
    • ,
  • Carlie J.M. de Vries

      Affiliations

    • Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • Erik N.T.P. Bakker

      Affiliations

    • Department of Biomedical Engineering and Physics, Academic Medical Center, PO Box 22700, 1100 DE Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 20 5665190; fax: +31 20 6917233.

Received 19 January 2010 ,Revised 14 July 2010 ,Accepted 27 July 2010.

References 

  1. AbdAlla S, Lother H, Langer A, el Faramawy Y, Quitterer U. Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis. Cell. 2004;119:343–354
  2. Boisvert WA, Rose DM, Boullier A, et al. Leukocyte transglutaminase 2 expression limits atherosclerotic lesion size. Arterioscler Thromb Vasc Biol. 2006;26:563–569
  3. Van Herck JL, Schrijvers DM, De Meyer GR, et al. Transglutaminase 2 deficiency decreases plaque fibrosis and increases plaque inflammation in apolipoprotein-E-deficient mice. J Vasc Res. 2009;47:231–240
  4. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol. 2003;4:140–156
  5. Bakker EN, Pistea A, VanBavel E. Transglutaminases in vascular biology: relevance for vascular remodeling and atherosclerosis. J Vasc Res. 2008;45:271–278
  6. Baumgartner W, Weth A. Transglutaminase 1 stabilizes beta-actin in endothelial cells correlating with a stabilization of intercellular junctions. J Vasc Res. 2007;44:234–240
  7. Ohura N, Yamamoto K, Ichioka S, et al. Global analysis of shear stress-responsive genes in vascular endothelial cells. J Atheroscler Thromb. 2003;10:304–313
  8. Auld GC, Ritchie H, Robbie LA, Booth NA. Thrombin upregulates tissue transglutaminase in endothelial cells: a potential role for tissue transglutaminase in stability of atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 2001;21:1689–1694
  9. Akimov SS, Belkin AM. Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. Blood. 2001;98:1567–1576
  10. Dardik R, Krapp T, Rosenthal E, Loscalzo J, Inbal A. Effect of FXIII on monocyte and fibroblast function. Cell Physiol Biochem. 2007;19:113–120
  11. Jayo A, Conde I, Lastres P, Jimenez-Yuste V, Gonzalez-Manchon C. Possible role for cellular FXIII in monocyte-derived dendritic cell motility. Eur J Cell Biol. 2009;88:423–431
  12. Matlung HL, Groen HC, de Vos J, et al. Calcification locates to transglutaminases in advanced human atherosclerotic lesions. Am J Pathol. 2009;175:1374–1379
  13. Bakker EN, Buus CL, Spaan JA, et al. Small artery remodeling depends on tissue-type transglutaminase. Circ Res. 2005;96:119–126
  14. Bakker EN, Pistea A, Spaan JA, et al. Flow-dependent remodeling of small arteries in mice deficient for tissue-type transglutaminase: possible compensation by macrophage-derived factor XIII. Circ Res. 2006;99:86–92
  15. Pistea A, Bakker EN, Spaan JA, Hardeman MR, van Rooijen N, VanBavel E. Small artery remodeling and erythrocyte deformability in L-NAME-induced hypertension: role of transglutaminases. J Vasc Res. 2008;45:10–18
  16. Tarantino U, Oliva F, Taurisano G, et al. FXIIIA and TGF-beta over-expression produces normal musculo-skeletal phenotype in TG2−/− mice. Amino Acids. 2009;36:679–684
  17. van den Maagdenberg AM, Hofker MH, Krimpenfort PJ, et al. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem. 1993;268:10540–10545
  18. Lardenoye JH, Delsing DJ, de Vries MR, et al. Accelerated atherosclerosis by placement of a perivascular cuff and a cholesterol-rich diet in ApoE*3Leiden transgenic mice. Circ Res. 2000;87:248–253
  19. Freund KF, Doshi KP, Gaul SL, et al. Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation. Biochemistry. 1994;33:10109–10119
  20. el Alaoui S, Legastelois S, Roch AM, Chantepie J, Quash G. Transglutaminase activity and N epsilon (gamma glutamyl) lysine isopeptide levels during cell growth: an enzymic and immunological study. Int J Cancer. 1991;48:221–226
  21. Barsigian C, Stern AM, Martinez J. Tissue (type II) transglutaminase covalently incorporates itself, fibrinogen, or fibronectin into high molecular weight complexes on the extracellular surface of isolated hepatocytes. Use of 2-[(2-oxopropyl)thio] imidazolium derivatives as cellular transglutaminase inactivators. J Biol Chem. 1991;266:22501–22509
  22. Haroon ZA, Wannenburg T, Gupta M, Greenberg CS, Wallin R, Sane DC. Localization of tissue transglutaminase in human carotid and coronary artery atherosclerosis: implications for plaque stability and progression. Lab Invest. 2001;81:83–93
  23. Sumi Y, Inoue N, Azumi H, et al. Expression of tissue transglutaminase and elafin in human coronary artery: implication for plaque instability. Atherosclerosis. 2002;160:31–39
  24. Williams H, Pease RJ, Newell LM, et al. Effect of transglutaminase 2 (TG2) deficiency on atherosclerotic plaque stability in the apolipoprotein E deficient mouse. Atherosclerosis. 2010;210:94–99
  25. Kawai J, Ando K, Tojo A, et al. Endogenous adrenomedullin protects against vascular response to injury in mice. Circulation. 2004;109:1147–1153
  26. Ozumi K, Tasaki H, Takatsu H, et al. Extracellular superoxide dismutase overexpression reduces cuff-induced arterial neointimal formation. Atherosclerosis. 2005;181:55–62
  27. Iismaa SE, Mearns BM, Lorand L, Graham RM. Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol Rev. 2009;89:991–1023
  28. Nahrendorf M, Aikawa E, Figueiredo JL, et al. Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction. Eur Heart J. 2008;29:445–454
  29. Iyer S, Ferreri DM, DeCocco NC, Minnear FL, Vincent PA. VE-cadherin-p120 interaction is required for maintenance of endothelial barrier function. Am J Physiol Lung Cell Mol Physiol. 2004;286:L1143–L1153
  30. Kojima S, Nara K, Rifkin DB. Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells. J Cell Biol. 1993;121:439–448
  31. Jensen PH, Lorand L, Ebbesen P, Gliemann J. Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa. Transglutaminase-catalyzed cross-linking to cellular and extracellular structures. Eur J Biochem. 1993;214:141–146

PII: S0021-9150(10)00599-X

doi: 10.1016/j.atherosclerosis.2010.07.054

Atherosclerosis
Volume 213, Issue 1 , Pages 77-84 , November 2010

Article Tools

* Image Usage & Resolution